Separately, Zacks Investment Research lowered Vapotherm from a “buy” rating to a “hold” rating in a research report on Saturday, October 5th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Vapotherm presently has a consensus rating of “Buy” and a consensus target price of $23.67.
NYSE VAPO traded down $0.06 during trading hours on Monday, reaching $10.59. The company’s stock had a trading volume of 135,177 shares, compared to its average volume of 110,842. The firm has a market capitalization of $224.92 million and a price-to-earnings ratio of -0.77. Vapotherm has a 1-year low of $7.60 and a 1-year high of $24.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.61 and a quick ratio of 6.81. The company’s 50-day moving average is $10.35 and its two-hundred day moving average is $14.14.
In other news, Director Elizabeth H. Weatherman purchased 8,382 shares of the stock in a transaction dated Friday, September 6th. The stock was acquired at an average cost of $11.38 per share, for a total transaction of $95,387.16. Also, CEO Joseph Army purchased 10,000 shares of the stock in a transaction dated Friday, November 8th. The shares were purchased at an average price of $9.48 per share, with a total value of $94,800.00. Insiders purchased 66,382 shares of company stock valued at $631,807 over the last quarter. 34.40% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC acquired a new stake in shares of Vapotherm in the third quarter valued at $42,000. Rhumbline Advisers acquired a new stake in shares of Vapotherm in the third quarter valued at $113,000. Barclays PLC raised its stake in shares of Vapotherm by 394.1% in the third quarter. Barclays PLC now owns 15,036 shares of the company’s stock valued at $142,000 after acquiring an additional 11,993 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Vapotherm in the third quarter valued at $184,000. Finally, California State Teachers Retirement System raised its stake in shares of Vapotherm by 214.3% in the third quarter. California State Teachers Retirement System now owns 22,841 shares of the company’s stock valued at $216,000 after acquiring an additional 15,574 shares in the last quarter. Institutional investors and hedge funds own 59.95% of the company’s stock.
Vapotherm Company Profile
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.